Storys zum Thema Therapie

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...

Gerresheimer AG

Gerresheimer at CPHI: focus on high-value solutions and sustainability

Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...

Takeda Pharma Vertrieb GmbH & Co. KG

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...

Helmholtz Zentrum München

Take a Deep Breath: Early Detection of Vascular Disease in Chronic Lung Disease of Premature Infants

Premature infants often struggle with breathing and require ventilatory support and oxygen therapy. Unfortunately, this might lead to lung damage resulting in lifelong consequences and chronic disease. Dr. Anne Hilgendorff’s team from Helmholtz Munich and the LMU University Hospital developed a non-invasive ...

STADA Arzneimittel AG

2

Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals

Helmholtz Zentrum München

A New Ally in Fighting Brain Diseases: Our Very Own Skull

ARTTIC Innovation GmbH

2

CARAMBA: New Hope for Multiple Myeloma Patients

Helmholtz Zentrum München

New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction

RHEACELL GmbH und Co. KG

RHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected

Grünenthal Group

Empowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced

Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...

Medias Klinikum GmbH & Co KG

The Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre

Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER

Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...

Grünenthal Group

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...

LTS Lohmann Therapie-Systeme AG

LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business

Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the ...

Debiopharm International SA

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...

Debiopharm International SA

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...

lino Biotech AG

Miltenyi Biotec acquires biosensor company lino Biotech

Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...

Medias Klinikum GmbH & Co KG

The world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission

CO.DON GmbH

CO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg

Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...

RHEACELL GmbH und Co. KG

Stem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research

Klinik für Prostata-Therapie Heidelberg

Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment

European Society for Medical Oncology (ESMO)

ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability

Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...

Technische Universität München

A repair program for the heart

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37376 Images: https://mediatum.ub.tum.de/1658419 NEWS RELEASE A repair program for the heart Cardiac progenitor cells generate healthy tissue after a heart attack Following a heart attack, the human body is incapable of repairing lost tissue due to the heart’s ...